**Stephen J. Nicholls, MBBS, PhD, FACC**
**Director of Victorian Heart Hospital**
South Australian Health & Med Res Inst

**Printed as of 11/18/2026**

# Disclosures

## Personal Commercial (32)

| Company Name | Relationship Category | Compensation Level | *Topic Area(s)* |
|---|---|---|---|
| *Self* | | | |
| Abcentra | Consultant Fees/Honoraria | Significant (>= $5,000) | |
| Amgen | Research/Research Grants | Significant (>= $5,000) | *Prevention* |
| Amgen Inc. | Consultant Fees/Honoraria | Modest (< $5,000) | *Prevention* |
| AstraZeneca | Research/Research Grants | Significant (>= $5,000) | *Prevention* |
| AstraZeneca | Consultant Fees/Honoraria | Modest (< $5,000) | *Prevention* |
| Atheronova | Research/Research Grants | Significant (>= $5,000) | *Prevention Vascular Medicine* |
| Boehringer Ingelheim | Consultant Fees/Honoraria | Modest (< $5,000) | *Prevention* |
| Cerenis | Consultant Fees/Honoraria | Modest (< $5,000) | *Prevention Vascular Medicine* |
| Cerenis | Research/Research Grants | Significant (>= $5,000) | *Vascular Medicine Prevention* |
| CRISPR Therapeutics | Research/Research Grants<br>‡ *Phase 1 trial* | Significant (>= $5,000) | |
| CSL Behring | Consultant Fees/Honoraria | Modest (< $5,000) | *Prevention* |
| CSL Sequiris | Consultant Fees/Honoraria | None ($0) | *Prevention* |
| Cyclarity | Research/Research Grants | Significant (>= $5,000) | |
| Daiichi Sankyo | Consultant Fees/Honoraria | Modest (< $5,000) | *Prevention* |
| Eli Lilly | Research/Research Grants | Significant (>= $5,000) | *Prevention* |
| Eli Lilly and Company | Consultant Fees/Honoraria | Modest (< $5,000) | *Prevention* |
| InfraReDx | Research/Research Grants | Significant (>= $5,000) | *Invasive CV Angio and Interventions* |
| Merck Schering-Plough | Consultant Fees/Honoraria | Modest (< $5,000) | *Prevention* |
| New Amsterdam Pharma | Stock | Modest (< $5,000) | |
| New Amsterdam Pharma | Research/Research Grants<br>‡ *PREVAIL* | Significant (>= $5,000) | |
| Novartis | Research/Research Grants | Significant (>= $5,000) | *Prevention* |
| Novo Nordisk Inc. | Consultant Fees/Honoraria | Modest (< $5,000) | *Prevention* |
| Omthera | Consultant Fees/Honoraria | Modest (< $5,000) | *Prevention* |
| Pfizer | Consultant Fees/Honoraria | Modest (< $5,000) | *Prevention* |
| Resverlogix | Consultant Fees/Honoraria | Modest (< $5,000) | *Prevention* |
| Resverlogix | Research/Research Grants | Significant (>= $5,000) | *Prevention* |
| Roche | Consultant Fees/Honoraria | Modest (< $5,000) | *Prevention* |
| Sanofi-Regeneron | Research/Research Grants | Significant (>= $5,000) | *Prevention* |
| Sanofi-Regeneron | Consultant Fees/Honoraria | Modest (< $5,000) | *Prevention* |
| Scribe Therapeutics | Research/Research Grants<br>‡ *Phase 1 trial* | Significant (>= $5,000) | |
| Takeda | Consultant Fees/Honoraria | Modest (< $5,000) | *Prevention* |
| Vaxxinity | Research/Research Grants<br>‡ *phase 1* | Significant (>= $5,000) | *Prevention* |

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

*† Commercial Funding Source | ‡ Trial Name*

## Agreement

**Certified Education Attestation** | Signed on 10/14/2026
*URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement*

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 10/14/2026
*URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement*

**Embargo** | Signed on 10/14/2026
*URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement*

**On-Going Obligation Agreement** | Signed on 10/14/2026

### ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.